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BLM, WRN, and p53 are involved in the homologous
DNA recombination pathway. The DNA structure-spe-
cific helicases, BLM and WRN, unwind Holliday junc-
tions (HJ), an activity that could suppress inappropriate
homologous recombination during DNA replication.
Here, we show that purified, recombinant p53 binds to
BLM and WRN helicases and attenuates their ability to
unwind synthetic HJ in vitro. The p53 248W mutant
reduces abilities of both to bind HJ and inhibit helicase
activities, whereas the p53 273H mutant loses these
abilities. Moreover, full-length p53 and a C-terminal
polypeptide (residues 373–383) inhibit the BLM and
WRN helicase activities, but phosphorylation at Ser376
or Ser378 completely abolishes this inhibition. Following
blockage of DNA replication, Ser15 phospho-p53, BLM,
and RAD51 colocalize in nuclear foci at sites likely to
contain DNA replication intermediates in cells. Our re-
sults are consistent with a novel mechanism for p53-
mediated regulation of DNA recombinational repair
that involves p53 post-translational modifications and
functional protein-protein interactions with BLM and
WRN DNA helicases.
Bloom and Werner syndromes (BS and WS)1 are autosomal
recessive disorders characterized by immune deficiency, cancer
predisposition, and chromosomal instability (1). The products
of the genes responsible for these disorders, BLM and WRN,
are ATP-dependent DNA helicases that exhibit 3 to 5 polarity.
Mutations in the BLM or WRN genes disrupt their helicase
activity, which may be important for the phenotypic traits
associated with these hereditary diseases (2).
Homologous recombination (HR) is required for genetic ex-
change during meiosis, repair of complex lesions in DNA, and
the segregation of chromosomes at cell division. Expression of
the BLM or WRN helicases in Saccharomyces cerevisiae con-
taining a mutation in sgs1, a BLM and WRN homolog, sup-
presses their increased rates of illegitimate recombination and
HR (3). BLM and its yeast homologue, Sgs1, functionally inter-
act with topoisomerase III (4), whereas the WRN interaction
with DNA polymerase  is apparently required for some aspect
of DNA replication and/or repair (5, 6). Recent reports indicate
that both of these helicases recognize and disrupt alternative
DNA structures, including G-quadruplex DNA and Holliday
junctions (HJ) (7–11). HJ arise as intermediates during HR
and can occur spontaneously, or during DNA replication and
the repair of DNA damage (12). BLM and WRN may promote
ATP-dependent translocation of HJ to eliminate DNA recom-
bination intermediates, thereby reducing inappropriate DNA
recombination in vivo (10, 11).
p53 suppresses genomic instability, particularly in response
to DNA damage (13, 14). p53 also has been implicated in HR.
Evidence of p53 modulation of HR includes the following: (a)
overexpression of wild-type p53 (WT p53) can down-regulate
the rate of HR between SV40 molecules (15); (b) the rate of HR
is increased in p53 mutant cell lines (16–18); (c) p53 has 3 to
5 exonuclease and DNA strand transfer activities (19); and (d)
p53 can bind and inhibit human RAD51 and bacterial RecA,
central components of the HR pathway (20, 21). In vitro, p53
also can bind to the crossover region of HJ (22), positively or
negatively supercoiled DNA (23, 24), and DNA base mis-
matches (25); all of these structures can be associated with HR.
p53 physically and functionally interacts with BLM and
WRN in vivo and in vitro (26–28). We hypothesize that p53
may regulate HR through its modulation of the BLM and WRN
helicase activities. In this study, we present the first evidence
that p53 modulates the ability of BLM and WRN helicases to
disrupt HJ. This property can be altered by modifications to the
p53 C terminus at Ser376 or Ser378. These modifications de-
crease modulation of recombination and abrogate the binding
of p53 to BLM. p53-mediated inhibition of BLM or WRN heli-
case activity apparently occurs through direct binding to these
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helicases. In addition, we show that p53 colocalizes in vivo with
BLM and RAD51 at putative sites of stalled DNA replication
forks and HJ in cells arrested in S-phase by aphidicolin (APH).
These results indicate a possible physiological mechanism for
the regulation of HR by the physical and functional interaction
of p53 with the BLM and WRN DNA helicases as well as their
DNA substrates.
EXPERIMENTAL PROCEDURES
Cell Culture, Western Blot Analyses, and Immunoprecipitation—
GM01310, a normal human lymphoblastoid cell line, was maintained at
a density greater than 3  105 cells/ml in RPMI medium supplemented
with 15% fetal bovine serum, penicillin, and streptomycin (Biofluids).
Human WI-38 and GM08402 fibroblasts were used at early passage.
Western blot analysis and immunoprecipitation were performed as
described previously (27).
Proteins and Antibodies—Recombinant hexahistidine-tagged human
BLM and WRN proteins were purified as described previously (29, 30).
Human WT, 248W, and 273H p53 proteins were generated from recom-
binant baculoviruses in Sf9 insect cells, and purified using an anti-p53
(antibody PAb421, which recognizes the C terminus of p53) immunoaf-
finity column, as described previously (31). The concentrations of dia-
lyzed peak fractions of p53 were determined by silver staining and
quantified with a Pantropic p53 Rapid Format Assay kit (Oncogene
Research Products). RuvA protein was kindly provided by Dr. Michael
M. Cox (University of Wisconsin, Madison, WI). Protein kinase C (PKC)
and protein phosphatase 1 (PP1) were from UBI. Anti-BLM and anti-
WRN were from Santa Cruz (Santa Cruz, CA). PAb421, DO-1, Ser15
phospho-p53, and anti-RAD51 were from Oncogene Research Products.
DNA Substrates—The synthetic X-junction (four-arm junction, blunt
ends, X-12) was prepared by annealing four 50-mer oligonucleotides as
described previously (10, 32). Briefly, X12-1 was 5-32P-labeled and
annealed with X12-2, X12-3, and X12-4. The product was then purified
by separation through a 10% TBE gel, and recovered by electroelution
and dialysis. The linear blunt duplex DNA used as the nonspecific
competitor was prepared by annealing X12-1 with its complement. The
28-mer M13mp18 partial duplex substrate was constructed with a
28-mer oligonucleotide complementary to position 3960–3987 in
M13mp18. The substrate was labeled, annealed, and purified as de-
scribed previously (33).
Helicase Assays—The BLM helicase assay reactions contained the
32P-labeled X-junction in 20 mM Tris-HCl, pH 7.5, 1.25 mM MgCl2, 2 mM
ATP, 0.1 mg/ml BSA, and 1 mM dithiothreitol. The WRN helicase assay
reactions contained 40 mM Tris borate, pH 7.4, 5 mM MgCl2, 5 mM
dithiothreitol, and 2 mM ATP. Reactions were initiated by the addition
of BLM or WRN proteins, and they were incubated at 37 °C for 45 min.
The products were separated by electrophoresis through 10% nondena-
turing polyacrylaminde gels at 4 °C and visualized using a Phosphor-
Imager or film autoradiography and quantified using the ImageQuant
software (Amersham Biosciences). Helicase data shown are represent-
ative of at least three independent experiments.
Electrophoretic Mobility Gel Shift Assay (EMSA)—The DNA-binding
reactions (20 l) contained 20 mM triethanolamine-HCl, pH 7.5, 2 mM
MgCl2, 1 mM ATPS, 0.1 g/ml BSA, and 1 mM dithiothreitol, and
protein concentration as indicated in the figures. Reaction mixtures
were incubated at room temperature for 20 min and fixed in the pres-
ence of 0.25% glutaraldehyde for 10 min at 37 °C. The products were
separated by electrophoresis through 4% nondenaturing polyacryla-
minde gels at 4 °C for 3 h, and visualized using a PhosphorImager or
film autoradiography.
Electron Microscopic Visualization of the p53-HJ Interaction—HJ
substrates (Hol575) for electron microscopy were prepared as described
previously (22). p53DNA complexes were assembled by incubating 50
ng of DNA in a 50-l reaction containing 10 mM HEPES, pH 7.5, and
100 mM KCl for 20 min at room temperature using a 1:6 molar ratio of
HJ DNAs to p53 tetramers. The complexes were fixed with 0.6% glut-
araldehyde (v/v) for 10 min at room temperature followed by gel filtra-
tion using a 1-ml Bio-Gel A-5m (Bio-Rad) column to remove free protein
and fixatives. The samples were prepared for electron microscopy as
described previously (34). Briefly, the samples were adsorbed to thin
carbon foils supported by 400-mesh copper grids in the presence of
spermidine, then washed with a water/ethanol series, air dried, and
rotary shadowcast with tungsten. The grids were visualized in a
Phillips CM12. Images for publication were scanned with a Nikon 4500
AF film scanner and the contrast was adjusted with Adobe Photoshop
software.
ELISA and Far Western Blotting—BLM and WRN were diluted to a
concentration of 2 nM in carbonate buffer (0.016 M Na2CO3, 0.034 M
NaHCO3, pH 9.6) and were then used to coat appropriate wells of a
96-well ELISA plate. WT p53 or mutant p53 proteins were incubated at
0–20 nM in a binding buffer (50 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 5 mM
ATP, 100 g/ml BSA, and 50 mM NaCl) for 30 min at 24 °C. Then, DO-1
and secondary antibodies were added sequentially. Phosphatase sub-
strate (Sigma) was incubated for 1 h at 37 °C. The A405 values, corrected
for background with BSA, were expressed as the mean of three inde-
pendent experiments.
Far Western blotting was performed as described by Wu et al. (4).
BLM or WRN (200 ng) were run on a SDS-PAGE gel and transferred to
Hybond-ECL filters (Amersham Biosciences). Filters were denatured
and incubated with WT or mutant p53 proteins (200 ng/ml) for 1 h at
4 °C. Western analysis was then conducted to detect p53 using DO-1 as
the primary antibody.
Phosphorylation-Dephosphorylation—Phosphorylation-dephospho-
rylation of p53 proteins was performed as described (35). p53 protein
was incubated in a kinase reaction buffer with PKC (20 ng). The reac-
tions were stopped by the addition of a peptide PKC inhibitor. The
reaction mixture was then incubated in the presence or absence of
phosphatase PP1 (0.02 unit). Separate aliquots were analyzed by West-
ern blot or helicase assay.
In Vitro Protein Interaction—Glutathione S-transferase fusion p53
protein was produced in Escherichia coli and purified on glutathione-
Sepharose 4B beads according to the manufacturer (Amersham Bio-
sciences). BLM and WRN proteins were prepared using the TNT quick-
coupled transcription/translation system (Promega) in the presence of
[35S]methionine. In vitro binding assay was done in immunoprecipita-
tion buffer with rotation at room temperature for 2 h. After washing,
the samples were loaded on SDS-PAGE and separated by
electrophoresis.
Indirect Immunofluorescence—Cells in 4-well glass chamber slides
were cultured with 5 g/ml APH for 14 h, fixed, and stained, as de-
scribed (4), using anti-BLM, anti-RAD51, and/or Ser15 phospho-p53
antibodies. Images were analyzed by Confocal Assistant software or
Laser Sharp. Quantitation of nuclear foci was determined from 100
cells for each treatment. Data were obtained from at least three inde-
pendent experiments.
RESULTS
Modulation of the BLM and WRN Helicase Activities by
p53—Because the helicase activities of BLM and WRN are
necessary for the promotion of HJ branch migration (10, 11), a
key step in HR, we investigated the possibility that p53 mod-
ulates the ability of BLM and WRN to disrupt a radiolabeled
synthetic X-junction (X-12) substrate (blunt ends). This X-junc-
tion is a mimic of the HJ. Consistent with previous reports
(9–11), both purified recombinant BLM and WRN disrupted
the X-junction into one-armed (single-stranded DNA) and, to a
lesser extent, into two-armed products (Fig. 1). To test the
effect of p53 on BLM or WRN disrupting the X-junction, BLM
or WRN were incubated with the X-junction in the presence of
PAb421-immunopurified recombinant WT p53 (Fig. 1). WT p53
inhibited the activities of both BLM and WRN to similar ex-
tents. At 6 nM concentration, WT p53 inhibited both BLM and
WRN helicase activities by about 80%. Two recombinant p53
mutant proteins (248W and 273H) that correspond to hotspot
mutants found in human cancer were also tested. The p53
273H lacked this inhibitory activity, whereas the p53 248W
mutant protein had less effect (about 50% inhibition) on BLM
or WRN activity. In the absence of BLM or WRN, neither WT
p53 nor mutants p53 248W and p53 273H showed intrinsic
helicase activity (Fig. 1A).
To determine whether that inhibition of BLM and WRN
helicases by p53 is structure-specific, an M13 28-bp partial
duplex DNA substrate was incubated with BLM (6 nM) and
increasing amounts of p53 (0, 5, 10, and 20 nM monomer). As
shown in Supplemental Materials Fig. 1, p53 did not inhibit
BLM unwinding of the M13 partial duplex. Consistent with a
previous report that p53 does not inhibit WRN unwinding of a
partial duplex substrate (33), it suggests that inhibition of
BLM and WRN helicases by p53 is structure-specific.
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Specificity of BLM, WRN, and p53 Bound to HJ—Recombi-
nant p53 protein produced in baculovirus exists in a tetrameric
form and binds to its DNA consensus sites predominantly as a
tetramer or as higher molecular weight complexes (36–40). We
used EMSA to determine the specific binding of BLM, WRN, or
p53 to the X-junction. Consistent with previous data (10, 11,
22), BLM induced a single-shifted band, whereas both WRN
and p53 induced multiple-shifted bands (Fig. 2A). One possi-
bility is that a single molecule of BLM binds to the X-junction,
whereas WRN and p53 bind to this substrate either in different
oligomeric states or at multiple sites on the DNA molecule.
Whereas WT p53 bound efficiently to the X-junction, p53 248W
bound to a lesser degree, and p53 273H showed no detectable
binding activity (Fig. 2A). The shifted bands were competed
efficiently by the unlabeled X-junction, but not by double-
stranded DNA (blunt ends). The simultaneous addition of both
p53 and BLM to EMSA reactions resulted in an increased
intensity of the shifted bands with different mobility. The pres-
ence of both p53 and BLM in these shifted bands was confirmed
by Western blot analysis with either p53 or BLM antibody,
indicating the presence of a p53-BLMX-junction complex (Fig.
2B, bands 7 and 8). Similar results were obtained when WRN
and p53 were used on the EMSA analysis. Both proteins were
detected in the shifted bands (Fig. 2C).
Electron Microscopic Visualization of the p53-HJ Interac-
tion—To visualize HJ by electron microscopy, 4-way junctions
containing 500-bp arms (Hol575) were constructed as described
previously (22). The Hol575 DNA was incubated with WT p53
as well as p53 248W and p53 273H at room temperature for 20
min. The samples were fixed, processed through Bio-Gel A-5m
to remove free proteins and fixatives, and prepared for EM.
Examination of the WT p53 complexes with Hol575 showed
that a large number of the HJ DNAs had p53 bound at the
crossover point (Fig. 3A). The DNA molecules were scored (n 
300) and the results showed that 63% of the HJ had p53 bound
somewhere on the DNA. Of these bound molecules, 70% con-
tained p53 at the crossover point, 13% had protein bound along
an arm of the HJ, and 17% had p53 at an end of one arm. The
FIG. 1. Effect of WT or mutant p53 on BLM (panel A) or WRN
(panel B) helicase activity. The helicase assay used 6 nM BLM or
WRN proteins with the X-junction (1 fmol) in the absence (lane 3) or
presence (lanes 4–6) of 6 nM WT, 248W, or 237H p53 proteins. p53 was
incubated simultaneously with the BLM or WRN proteins and the
X-junction. The appearance of the faster migrating two-armed products
(small amount) and single-stranded (ss) DNA species indicates disrup-
tion of the X-junction. H, heat-denatured control.
FIG. 2. A, the binding of BLM, WRN, WT, 248W, or 273H p53 to
radiolabeled X-junction (2 fmol) was competed with double-stranded
DNA or unlabeled X-junction. N, double-stranded DNA (20-fold excess
over the radiolabeled X-junction). S, unlabeled X-junction (10-fold ex-
cess). B and C, 20 fmol of X-junction was incubated simultaneously with
BLM or WRN (120 nM) and/or WT p53 (120 nM) and analyzed by EMSA.
The shifted bands were cut and separated by SDS-PAGE following by
conventional Western blotting with anti-BLM, anti-WRN, or anti-p53
(DO-1).
FIG. 3. A, visualization of p53 bound to HJ. WT p53 (A), p53 248W
(B), and p53 273H proteins (C) were incubated with HJ containing
500-bp arms at a molar ratio of six p53 tetramers per DNA molecule.
Shown in reverse contrast. Bar is equivalent to 500 bp. B, competition
for binding of WRN or p53 to the X-junction by RuvA using EMSA.
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p53 248W showed slightly lower binding affinity than the WT
p53. Of the molecules scored, 40% of the molecules were bound
by p53. In addition, this mutant had lower affinity for the
crossover point of the junction. Of the bound molecules
counted, only 45% had protein at the crossover junction when
compared with 70% in WT p53. The remaining molecules had
p53 bound either along the arm or at the termini of the arms.
Finally, the p53 273H mutant showed very low binding to the
Hol575 template. Only 12% of the DNA molecules were bound
by the protein and, more interestingly, none of the bound
molecules had p53 at the crossover point. When compared with
the WT p53, this mutant not only had reduced binding to DNA,
but also had lost the specificity of the crossover point.
The E. coli RuvA protein specifically binds to HJ at the
crossover junction (41, 42). Here, it competed efficiently with
WRN or p53 for binding to the X-junction (Fig. 3B). In the
presence of a 3-fold excess of WRN or p53 over RuvA, the
RuvAX-junction complex predominated. This indicated that
the affinity of WRN and p53 for the X-junction is less than that
observed with RuvA. Consistent with a previous report (11),
similar results were seen with BLM (data not shown). These
data indicate that p53, BLM, and WRN recognize the DNA
crossover of the HJ.
Relationship between Binding to HJ and Inhibition of Heli-
case Activity by p53—Next, we compared the effects of various
concentrations of WT, 248W, or 273H p53 for their binding to
the X-junction and their inhibition of BLM or WRN helicase
activity. WT p53 bound to the X-junction and inhibited the
helicase activities of BLM and WRN in a dose-dependent man-
ner (Fig. 4). Binding of the p53 248W to the X-junction and
inhibition of BLM and WRN helicase activities were dose-de-
pendent, but the magnitude of the effect was reduced signifi-
cantly relative to that of WT p53. p53 273H did not signifi-
cantly bind to the X-junction nor inhibit helicase activity.
In Vitro and in Vivo Interaction of p53 with BLM or
WRN—To determine whether protein-protein interactions
were also responsible for p53-mediated modulation of the BLM
and WRN helicase activities in vivo, cell lysates were prepared
from either untreated or irradiated (5 gray) normal lympho-
blastoid cells (GM01310). The lysates were then subjected to
immunoprecipitation with anti-BLM or anti-WRN antibody.
The efficiency of the immunoprecipitation was assessed by
analyzing supernatants of the immunoprecipitation and
straight loadings of the cell lysates by Western blotting with
anti-BLM or anti-WRN antibody. Only about 20% BLM or
WRN proteins were immunoprecipitated by these antibodies
(data not shown).
A dilution series of recombinant p53 was used as a standard
for quantification of the amount of cellular p53. p53 increased
to 3.3  104 molecules/cell 3 h after irradiation (Fig. 5A),
whereas the amount of BLM was unchanged under these ex-
perimental conditions. Assuming that there are 4,000 mole-
cules of BLM/cell (43), the ratio of p53 to BLM is about 8:1.
Previous studies have suggested that active forms of BLM and
p53 are hexameric and tetrameric, respectively (30, 36). Hence,
the maximum calculated percentage of p53 that could be im-
munoprecipitated by anti-BLM antibodies is 12%. We found
that about 2% of the cellular p53 was immunoprecipitated by
anti-BLM or anti-WRN antibody after exposure to irradiation
(Fig. 5B). The efficiency of BLM or WRN immunoprecipitation
was only 20%, thus we conclude that approximately 10% of the
cellular p53 binds to either BLM or WRN under our conditions.
This is close to the theoretical maximum that could be immu-
noprecipitated by anti-helicase antibodies, indicating that both
helicases bind saturating amounts of p53. Because p53 is in
large excess, these results indicate that only a fraction of p53 is
involved in binding to helicases. Competitive peptides blocked
co-immunoprecipitation of p53 with anti-BLM or WRN exclud-
ing the possibility that the immunoprecipitation was nonspe-
cific (data not shown).
Direct binding of p53 to both BLM and WRN was confirmed
by far Western analysis. BLM, WRN, or p53 were separated by
SDS-PAGE and transferred to a nitrocellulose membrane,
which was then incubated with WT or mutant p53 proteins.
WT p53 and p53 248W exhibited strong binding to BLM or
WRN, whereas p53 273H showed weaker, but detectable, bind-
ing. BSA was used as a negative control (Fig. 5C).
We next analyzed the binding affinities of WT and mutant
p53 to BLM and WRN. Using an ELISA, WT p53 and p53 248W
bound in a dose-dependent manner, and with similar affinities,
to both BLM and WRN. In contrast, p53 273H showed a rela-
tively weak level of binding to either BLM or WRN (Fig. 5D).
The specificity of the interaction was demonstrated by the
absence of detectable signals in wells that had been precoated
with BSA only (data not shown).
Modifications to the p53 C Terminus Attenuate Its Inhibition
of BLM and WRN Helicase Activities—The p53 C terminus is
required for binding to both BLM or WRN (26–28) and may be
post-translationally modified (44, 45). Therefore, we deter-
mined whether modification of the p53 C terminus would alter
its ability to modulate the helicase activities of BLM and WRN
in a model system. PKC phosphorylates p53 in vitro at Ser378
FIG. 4. WT or mutant p53 binding to the X-junction and its
effect on BLM or WRN helicase activity. A, EMSA was carried out
with the X-junction (2 fmol) containing the indicated concentrations of
WT, 248W, or 273H p53 proteins. The percent binding was calculated
from the ratio of shifted bands to free probe. Percent DNA binding is
expressed as a function of p53 concentration. B, the X-junction (1 fmol)
was incubated with 6 nM BLM or WRN proteins in the absence or
presence of the indicated concentrations of WT, 248W, or 273H p53
under standard helicase assay conditions. Quantification of the prod-
ucts included two-armed and single-stranded DNA species. The relative
percent X-junction disruption is expressed as a function of p53
concentration.
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within the PAb421 antibody epitope, thereby reducing PAb421
reactivity (35, 46). PP1 dephosphorylates the PKC-reactive site
in p53 (35). Consistent with these reports, phosphorylation of
purified recombinant p53 protein by PKC significantly reduced
the reactivity of p53 to PAb421, but not to DO-1, an antibody
that targets the N terminus of p53 (Supplemental Materials).
Incubation of the PKC-treated p53 protein with phosphatase
PP1 effectively restored PAb421 reactivity.
The PKC-phosphorylated p53 protein exhibited reduced in-
hibition of BLM or WRN helicase activity relative to unmodi-
fied p53, whereas dephosphorylation of PKC-treated p53 pro-
tein by PP1 restored its activity (Fig. 6, A and B). With PKC-
phosphorylated p53 protein at a concentration of 9 nM, 28%
inhibition of BLM and 21% inhibition of WRN helicase activi-
ties were observed. Approximately 93% inhibition of both BLM
and WRN helicase activities was achieved using dephosphoryl-
ated PKC-treated p53, similar to the 94% inhibition seen when
using unmodified WT p53. In addition, PAb421, but not DO-1,
an antibody to the N terminus of p53, also blocked the inhibi-
tory effect of p53 on BLM and WRN helicase activities. Com-
pared with 45% inhibition of BLM, the PAb421p53 complex
gave only 12% inhibition of WRN.
FIG. 5. In vivo and in vitro interaction between p53 and BLM
or WRN. A, normal lymphoblastoid cell lines (GM01310, NL) were
treated with or without 5 gray -radiation and incubated for 2 h. Cell
lysates were analyzed by Western blotting (WB) with anti-p53 antibody
(DO-1) to quantify the cellular p53 amount, using recombinant p53 as
standards. B, cell lysates (10-fold amounts of WCE) were subjected to
immunoprecipitation with anti-BLM or anti-WRN antibody, followed by
Western blotting with anti-p53 antibody (DO-1) to quantitate immuno-
precipitated p53. WCE, whole cell extracts. C, detection of p53 interac-
tion with BLM and WRN by far Western blotting. BLM or WRN were
fixed to a nitrocellulose filter and incubated with purified WT p53, p53
248W, or p53 273H. The filter was then probed using the anti-p53 DO-1
antibody. WT and mutant p53 were loaded directly as positive controls
(lanes 3, 7, and 11) and BSA was used as a negative control (lanes 4, 8,
and 12). D, p53 binding to BLM or WRN was quantified by ELISA.
BLM- or WRN-precoated wells were incubated with WT or mutant p53
proteins. Bound p53 protein was detected using the DO-1 antibody. The
A405 values were corrected for background binding in the BSA-coated
wells. Symbols used are: WT p53-BLM, f; WT p53-WRN, ; p53 248W-
BLM, ; p53 248W-WRN, E; p53 273H-BLM, Œ; p53 273H-WRN, ‚.
FIG. 6. A and B, effect of modified p53 on BLM or WRN helicase
activity. BLM or WRN proteins (9 nM) were incubated with the X-junc-
tion (1 fmol) in the presence of WT p53 (9 nM), pAb421 (50 ng), DO-1 (50
ng, lane 5), PKC-phosphorylated p53 (9 nM p53, 20 ng of PKC), and/or
PP1-dephosphorylated p53 (9 nM p53, 20 ng of PKC, 0.02 unit) under
standard helicase reaction conditions. C, interaction of modified p53
with BLM or WRN. 2 g of glutathione S-transferase-p53 fusion pro-
teins were modified by PAb421, DO-1, PKC, or PKC PP1, as described
as above, then incubated with 5 l of in vitro translated BLM or WRN
proteins labeled with [35S]methionine to determine the binding affinity
of p53 with BLM and WRN. A 20% input of the BLM and WRN proteins
is included in lane 6 (from the same blot). Glutathione S-transferase-
p53 protein input was verified by Coomassie Blue staining.
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To examine whether modification of the p53 C terminus
altered binding to HJ, the binding affinities of PKC-phospho-
rylated p53 and dephosphorylated PKC-treated p53 to the X-
junction were determined by EMSA. The PKC-phosphorylated
p53 and dephosphorylated PKC-treated p53 had similar affin-
ities toward the X-junction as unmodified WT p53 (Supplemen-
tal Materials). To explore the mechanism of p53 inhibition of
BLM and WRN helicase activities, we examined binding affin-
ities between C-terminal-modified p53 and BLM or WRN pro-
teins. In agreement with the results of the helicase assays,
modification of the recombinant glutathione S-transferase-p53
fusion protein, through either PAb421 antibody or PKC phos-
phorylation, attenuated its ability to bind to BLM or WRN
proteins (Fig. 6C).
To further determine the requirement of the p53 C terminus
for the modulation of BLM and WRN helicase activity, a syn-
thetic p53 peptide corresponding to residues 373–383 was used
in the helicase assay. This p53 peptide exhibited a concentration-
dependent inhibition of BLM and WRN helicase unwinding of
the X-junction (Fig. 7, A and B). In contrast, the p53 peptide
phosphorylated at Ser376 (P1) or Ser378 (P2) was noninhibitory,
even at a high concentration (Fig. 7, A and B). These three
short peptides did not compete with p53 for binding to the
X-junction, whereas the longer p53 peptide (319–393 amino
acids) competed efficiently (Supplemental Materials). Taken
together, we conclude that a p53 C-terminal region containing
residues 373–383 is required for the interaction with and mod-
ulation of the branch migration activities of the BLM and WRN
helicases on HJ.
p53, BLM, and RAD51 Colocalize to Nuclear Foci—RAD51
protein catalyzes a key step in HR, and it accumulates in
nuclear foci that are thought to correspond to sites of stalled
replication forks and recombinational repair of DNA double-
strand breaks (47). BLM and RAD51 form a complex and colo-
calize to nuclear foci in cells arrested in S-phase using either
APH or hydroxyurea (47, 48), suggesting that these proteins
cooperate in the repair of breaks arising at stalled replication
forks. The effects of p53 on BLM disruption of HJ presented
here suggest that p53 may be involved in this process in vivo.
To test this hypothesis, we examined the localization of p53,
BLM, and RAD51 in cells treated with APH. Cell cycle distri-
bution was determined by flow cytometry (data not shown).
Consistent with previous reports (47, 48), BLM and RAD51
nuclear foci increased and colocalized in S-phase cells after
treatment with APH (Fig. 8). About 45% of the APH-treated
cells displayed Ser15 phospho-p53 nuclear foci, but none of the
untreated cells did. Quantitative analysis of the confocal mi-
croscopic pixels indicated that 63 and 39% of Ser15 phospho-p53
foci colocalized with BLM and RAD51, respectively (Fig. 8B).
Similarly, Ser15 phospho-p53, BLM, and RAD51 were found to
colocalize after S-phase arrest in U2OS cells, derived from a
human osteogenic sarcoma that contains WT p53 (data not
shown). These colocalization data provide in vivo evidence that
p53 may play a role in a recombinational repair pathway that
also includes BLM and RAD51.
DISCUSSION
p53-mediated Inhibition of BLM and WRN Helicase Activ-
ities—We report evidence that p53 inhibits the helicase ac-
tivities of both BLM and WRN. WT p53 inhibits BLM and
WRN helicase disruption of the X-junction more efficiently
than p53 248W, whereas p53 273H lacks this activity. Muta-
tions in p53 including codons 248 and 273 are observed
frequently in human cancers (49, 50). The influence of these
missense mutations on DNA binding and protein conforma-
tion is still unclear. Most of the mutants at codons 248 and
273 do not display any obvious change in their protein con-
FIG. 7. A and B, effects of C-terminal peptides of p53 on BLM or WRN
helicase activity. BLM or WRN proteins were incubated with the X-
junction (1 fmol) in the presence of C-terminal peptides of p53 under
standard helicase reaction conditions.
FIG. 8. Increasing colocalization of p53 with BLM or RAD51 in
cells treated with APH. A, WI-38 cells were stained with anti-BLM,
anti-RAD51, and/or anti-Ser15 phospho-p53 antibodies, and nuclei were
stained with 4,6-diamidino-2-phenylindole. Untreated cells were used
as controls. B, quantitation of nuclear foci (mean  S.D.) was deter-
mined from 100 cells analyzed by Confocal Assistant software or Laser
Sharp. Data were obtained from at least three independent experi-
ments. Student’s t test was used for analyzing the statistical signifi-
cance of colocalization between p53-BLM and BLM-p53 (p  0.5), p53-
RAD51 and RAD51-p53 (p 	 0.5), and BLM-RAD51 treated and
untreated (p  0.01) groups.
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formation, as determined by reactivity to antibodies PAb240
or PAb1620, or by binding to hsp70 protein (51). Analysis of
the crystal structure of p53 reveals that both 248 and 273
residues contact the DNA directly (52). WT p53 exerts an
inhibitory effect on the exonuclease activity of WRN, whereas
the p53 273H mutant does not (33). Recent studies indicate
that WT p53 inhibits recombinational processes when en-
countering mismatches in heteroduplexes, but p53 273H is
significantly defective in this function (18). Our results indi-
cate that WT p53 can regulate members of the RecQ helicase
family involved in recombinational repair, but that the p53
273H mutant lacks this function. These data are consistent
with the hypothesis that WT p53 plays a functional role in
the helicase-HR pathway.
Effects of Modifications to the p53 C Terminus on Helicase
Activity—The p53 C terminus contains several important phos-
phorylation sites that affect p53-mediated function (44, 45). For
example, p53 can be regulated positively or negatively by re-
versible PKC modifications in vitro, affecting the latent or
active state of the protein (35, 45), although it is uncertain
whether or not PKC phosphorylates p53 in vivo (53–55). Cer-
tain types of cellular stress, e.g. ionizing irradiation, lead to
rapid dephosphorylation of p53 at Ser376 (46, 56). Recent re-
ports have shown that p53 binds to BLM or WRN in vivo and in
vitro and that p53 lacking the C terminus does not bind to these
helicases (26–28). Based on the data presented here, the p53 C
terminus is involved in the inhibition of the BLM and WRN
helicase activities. p53-mediated inhibition of BLM or WRN
helicase activity is reduced by modification of p53 through
either the binding of PAb421, a p53-specific antibody that binds
to a C-terminal epitope, or phosphorylation at Ser376 and
Ser378, which inhibits its binding to BLM or WRN. Further-
more, a p53 C-terminal polypeptide (residues 373–383) is suf-
ficient to inhibit BLM or WRN helicase activity, whereas a
peptide phosphorylated at Ser376 or Ser378 lacks this activity.
Taken together, our data provide direct evidence that post-
translational modification of the p53 C terminus regulates its
interaction with these DNA helicases. The fact that this small
C-terminal peptide inhibits helicase activity and that the inhi-
bition can be reversed by phosphorylation indicates that the
p53 C terminus contains an active site. Post-translational mod-
ification of p53 in response to DNA strand breaks may be a
molecular switch that regulates the functional interaction be-
tween p53 and DNA helicases.
Insight into the Mechanism of p53-mediated BLM and WRN
Helicase Activities—BLM specifically binds to HJ, but fails to
form a stable complex with linear, blunt-ended duplex DNA
that contains a sequence identical to that of one of the “arms”
of HJ (11). This indicates that BLM binds strongly to the
crossover region of HJ. WRN also binds to HJ (10). The activity
of WRN on recombination intermediates is due, at least in part,
to the recognition of the junction within the duplex DNA
substrate.
Here, we report that the binding affinity of WT p53 to a
mimic of the HJ is higher than that of the p53 248W mutant,
and that p53 273H lacks this binding ability. Because abilities
of WT p53, p53 248W, and p53 273H proteins to bind to the
X-junction correlate with their capacity to inhibit BLM and
WRN helicase activities, it is possible that p53 binding to the
DNA substrate may be required for p53-mediated inhibition of
the helicase activity. However, both helicases also interact
physically with WT p53, as shown by far Western blotting and
ELISA, indicating that p53 may also modulate the helicase
activity by binding directly to the BLM or WRN proteins.
Consistent with this latter hypothesis, modification of the p53
C terminus leads to an attenuation of p53-mediated inhibition
on BLM and WRN helicase activities, but does not impair its
binding to the X-junction. These findings are strong evidence
that inhibition of BLM and WRN helicase activities by p53 is
mediated by direct interaction with BLM and WRN, and not
with the HJ substrate.
p53 as a Cofactor in BLM-RAD51 HR Pathway—RAD51 is a
central component of the HR pathway that is involved in DNA
double-strand break repair (47). One major role for HR that has
emerged in recent years is to facilitate the reinitiation of rep-
lication following replication fork collapse. Removal of HJ is
necessary following such repair. Interaction between BLM and
RAD51 may, therefore, serve to recruit BLM to the sites of
recombinational repair (47, 57). BLM disrupts HJ by branch
migration, and the loss of BLM would give rise to excessive
recombination, corresponding to the genome-wide hyper-re-
combination and genomic instability in BLM-deficient cells.
p53 binds to RAD51 and is involved in recombinational repair
(20), and p53-deficient cells show hyper-recombination (16–18,
21). One model is that p53 or other proteins, e.g. RAD51 (47),
recruit BLM and WRN to HJ and participate in the assembly of
the multiprotein HR complex (28). The physical and functional
interactions between these DNA helicases and p53 may be
regulated either by its post-translational modification, consist-
ent with the data shown here, or by other proteins in the HR
complex. Further studies are needed to refine this model. Con-
sistent with previous reports that WRN copurifies with a DNA
replication complex (58) and binds to p53 (26, 27), p53 may
regulate the anti-recombinase functions of the human RecQ
helicase family members that are critical for the maintenance
of genomic stability.
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